An updated brand for the future of Sequence Bio

Over the past few years, the work we do at Sequence Bio has purposefully evolved. Today, we are marking that growth with an updated brand that better reflects our ultimate goal to discover the future of medicine.

This is more than just a new look. It represents the next chapter in our mission made possible by years of foundational work. Our deep understanding of the Newfoundland and Labrador founder population has enabled us to start the search for the genetic causes of some of the most medically challenging diseases.

We are now leading a diverse portfolio of genetic discovery programs, and conducting target identification and validation science in-house, to uncover novel pathways for the discovery and development of life-changing medicines.

As our business continues to grow, our core values have only deepened. Our commitment to innovating with integrity—putting ethics, privacy, and security at the heart of everything we do—is unwavering. We are also incredibly proud to support our promise of returning benefits with a landmark Benefits and Royalty Agreement with the Government of Newfoundland and Labrador, helping to ensure that those who contribute to our research also benefit from its advances.

This next chapter for Sequence Bio is a shared one. For our team, it means tackling the exciting new challenges we have been working towards. For our collaborators and research participants, it means your partnership is as essential as ever to help realize the full, global potential of this homegrown research.

We invite you to explore our new look and website, and hope you feel the same excitement we do for the journey ahead.

Lynn Healey
Chief Executive Officer